NCT05000294 2026-06-05Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesUniversity of FloridaPhase 1/2 Recruiting29 enrolled
NCT05652686 2025-09-23A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)Phanes TherapeuticsPhase 1/2 Recruiting203 enrolled